Autor según el artículo: López-Sánchez A, Pérez-Cantero A, Torrado-Salmerón C, Martin-Vicente A, García-Herrero V, González-Nicolás MÁ, Lázaro A, Tejedor A, Torrado-Santiago S, García-Rodríguez JJ, Capilla J, Torrado S

Departamento: Ciències Mèdiques Bàsiques

Autor/es de la URV: Capilla Luque, Javier

Palabras clave: Toxicity evaluation Therapy Pulmonary concentrations Nervous-system aspergillosis Nephrotoxicity Nanoparticles Murine model Lipid complex Immunosuppressed mice Fungal-infections Efficacy Deoxycholate Comparative pharmacodynamics Aspergillosis Antifungal Amphotericin b

Resumen: An experimental micellar formulation of amphotericin B (AMB) with sodium deoxycholate (DCH), AMB:DCH 1:1.5, was obtained and characterized to determine its aggregation state and particle size. Biodistribution, nephrotoxicity and efficacy against pulmonary aspergillosis in a murine model were studied and compared to the liposomal commercial amphotericin B after intravenous administration. The administration of 5 mg/kg AMB:DCH 1:1.5 presented 2.8-fold higher lung concentrations (18.125 ± 3.985 μg/g, after 6 daily doses) and lower kidney exposure (0.391 ± 0.167 μg/g) compared to liposomal commercial amphotericin B (6.567 ± 1.536 and 5.374 ± 1.157 μg/g, in lungs and kidneys, respectively). The different biodistribution of AMB:DCH micelle systems compared to liposomal commercial amphotericin B was attributed to their different morphology and particle size. The efficacy study has shown that both drugs administered at 5 mg/kg produced similar survival percentages and reduction of fungal burden. A slightly lower nephrotoxicity, associated to amphotericin B, was observed with AMB:DCH 1:1.5 than the one induced by the liposomal commercial formulation. However, AMB:DCH 1:1.5 reached higher AMB concentrations in lungs that could represents a therapeutic advantage over liposomal commercial amphotericin B-based treatment of pulmonary aspergillosis. These results are encouraging to explore the AMB:DCH 1:1.5 usefulness against this disease.Copyright © 2018 American Society for Microbiology.

Áreas temáticas: Saúde coletiva Química Pharmacology (medical) Pharmacology & pharmacy Pharmacology Odontología Nutrição Microbiology Medicina veterinaria Medicina iii Medicina ii Medicina i Materiais Matemática / probabilidade e estatística Interdisciplinar Infectious diseases Farmacia Ensino Engenharias iv Engenharias iii Engenharias ii Enfermagem Educação física Educação Ciências biológicas iii Ciências biológicas ii Ciências biológicas i Ciências agrárias i Ciência de alimentos Biotecnología Biodiversidade Astronomia / física

Acceso a la licencia de uso: https://creativecommons.org/licenses/by/3.0/es/

ISSN: 00664804

Direcció de correo del autor: javier.capilla@urv.cat

Identificador del autor: 0000-0002-0765-6403

Fecha de alta del registro: 2023-02-18

Versión del articulo depositado: info:eu-repo/semantics/acceptedVersion

Enlace a la fuente original: https://aac.asm.org/content/62/7/e00489-18

URL Documento de licencia: http://repositori.urv.cat/ca/proteccio-de-dades/

Referencia al articulo segun fuente origial: Antimicrobial Agents And Chemotherapy. 62 (7):

Referencia de l'ítem segons les normes APA: López-Sánchez A, Pérez-Cantero A, Torrado-Salmerón C, Martin-Vicente A, García-Herrero V, González-Nicolás MÁ, Lázaro A, Tejedor A, Torrado-Santiago S (2018). Efficacy, Biodistribution, and Nephrotoxicity of Experimental Amphotericin B-Deoxycholate Formulations for Pulmonary Aspergillosis. Antimicrobial Agents And Chemotherapy, 62(7), -. DOI: 10.1128/AAC.00489-18

DOI del artículo: 10.1128/AAC.00489-18

Entidad: Universitat Rovira i Virgili

Año de publicación de la revista: 2018

Tipo de publicación: Journal Publications